Cancer Research and Treatment10.4143/crt.2019.1832020521149-166Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic CancerMei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, Do-Youn Oh,,
10.21203/ downregulates PD-L1 expression through HDAC6 in malignant melanomaRuwei Xing, Ting Li, Lijie Xiang, Haotian Liu, Junqiang Wei, Jia Lu, Jilong Yang,
Bulletin du Cancer10.1016/j.bulcan.2017.11.01220181053263-274Expression de PD-L1 et inhibiteurs de la voie PD-1/PD-L1 dans le cancer du seinAudrey Monneur, Anthony Gonçalves, François Bertucci,
10.21203/rs.2.24485/v12020Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancerChao Zhang, Wen An, Yuen Tan, Huimian Xu,
Current Oncology10.3747/co.25.39762018254324-334Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung CancerD.E. Meyers, P.M. Bryan, S. Banerji, D.G. Morris,,
Gastroenterology10.1016/s0016-5085(17)30942-320171525S189Effectiveness of PD-L1 Inhibition as a Therapeutic Option of Cancer Immunotherapy in Pancreatic CancerEri Kameta, Wataru Shibata, Takeshi Sato, Soichiro Sue, Shin Maeda,
Therapeutic Advances in Urology10.1177/1756287215597647201576365-377Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinomaMatthew Weinstock, David McDermott,,
BMJ10.1136/bmj.k35292018k3529Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysisXian Shen, Bin Zhao,
Journal for ImmunoTherapy of Cancer10.1136/jitc-2019-000157corr1202081e000157corr1Correction:HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Disease Markers10.1155/2020/8843146202020201-7PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic CancerLei Zhao, Yaming Cao,,